Yi-gan san for treatment of charles bonnet syndrome (Visual hallucination due to vision loss): An open-label study

Clinical Neuropharmacology

Volumn 34, Issue 1, 2011, Pages 24-27

  Miyaoka, Tsuyoshi ^a   Furuya, Motohide ^a   Kristian, Liaury ^a   Wake, Rei ^a   Kawakami, Kazunori ^a   Nagahama, Michiharu ^a   Kawano, Kiminori ^a   Ieda, Masa ^a   Tsuchie, Keiko ^a   Horiguchi, Jun ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

5 HT; Charles Bonnet syndrome; GABA; hallucinations; NMDA; open label study; yi gan san

Indexed keywords

HERBACEOUS AGENT; UNCLASSIFIED DRUG; YI GAN SAN;

ADULT; AGED; ARTICLE; CHARLES BONNET SYNDROME; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOMETRY; SCORING SYSTEM; SINGLE BLIND PROCEDURE; VISUAL IMPAIRMENT;

AGED; AGED, 80 AND OVER; AGING; DRUGS, CHINESE HERBAL; FEMALE; HALLUCINATIONS; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; VISION, LOW;

EID: 79551600221     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318206785a     Document Type: Article

References (34)

1. Rovner BW. The Charles Bonnet syndrome: a review of recent research. Curr Opin Ophthalmol 2006;17:275-277.
2. Kester EM. Charles Bonnet syndrome: case presentation and literature review. Optometry 2009;80:360-366.
3. Hof PR, Bouras C, Constantinidis J, et al. Selective disconnection of specific visual association pathways in cases of Alzheimer's disease presenting with Balint's syndrome. J Neuropathol ExpNeurol 1990;49:168-184.
4. Pliskin NH, Kiolbasa TA, Towle VL, et al. Charles Bonnet syndrome: an early marker for dementia? Am Geriatr Soc 1996;44:1055-1061.
5. Ashwin PT, Tsaloumas MD. Complex visual hallucinations (Charles Bonnet syndrome) in the hemianopic visual field following occipital infarction. J Neurol Sci 2007;263:184-186.
6. Haddad PM, Benbaw SM. Visual hallucination as the presenting symptom of senile dementia. Br J Psychiatr 1992;161:263-265.
7. Menon GJ, Rahman I, Menon SJ, et al. Complex visual hallucinations in the visually impaired: the Charles Bonnet syndrome. Sur Ophthalmol 2003;48:58-72.
8. Menon GJ. Complex visual hallucinations in the visually impaired. Arch Ophthalmol 2005;123:349-355.
9. Loberboym M, Lampl Y, Gilad R, et al. Tc-99m ethylcystenate dimer brain SPECT perfusion imaging in ictal nonepileptic visual hallucinations. Clin NuclMed 2002;27:87-91.
10. Hori H, Terao T, Shiraishi Y. Treatment of Charles Bonnet syndrome with valproate. In Clin Psychopharmacol 2000;15:117-119.
11. Pauling M, Mentrup H. Charles Bonnet syndrome: complete remission of complex visual hallucinations treated by gabapentin. J Neurol Neurosurg Psychiatry 2001;70:813-814.
12. Maeda K, Shirayama Y, Nukina S, et al. Charles Bonnet syndrome with visual hallucinations of childhood experience: successful treatment of 1 patient with risperidone. J Clin Psychiatry 2003;64:1131-1132.
13. Moja MC, Milano E, Gasverde S, et al. Olanzapine therapy in hallucinatory visions related to Bonnet syndrome. Neurol Sci 2005;26:168-170.
14. Lang UE, Stogowski D, Schulze D, et al. Charles Bonnet syndrome: successful treatment of visual hallucinations due to vision loss with selective serotonin reuptake inhibitors. J Psychopharmacol 2007;21:553-555.
15. Aizawa R, Kanbayashi T, Saito Y, et al. Effect of yoku-kan-san-ka-chinpi- hange on the sleep ofnormal healthy adult subjects. Psychiatry Clin Neurosci 2002;56:303-304.
16. Iwasaki K, Satoh-Nakagawa T, Maruyama M. A randomized observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement ofbehavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry 2005;66:248-252.
17. Miyaoka T, Furuya M, Yasuda H, et al. Yi-gan san for treatment of borderline personality disorder: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:150-154.
18. Miyaoka T, Furuya M, Yasuda H, et al. Yi-gan san for treatment of neuroleptic-induced tardive dyskinesia: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:761-764.
19. Miyaoka T, Furuya M, Yasuda H, et al. Yi-gan san as adjunctive therapy for treatment-resistant schizophrenia: an open-label study. Clin Neuropharmacol 2009;32:6-9.
20. Miyaoka T, Horiguchi J. Clinical potential of Yi-gan san (Yokikansan) for psychiatric disorders. Curr Psychiatry Rev 2009;5:271-275.
21. Miyaoka T, Furuya M, Yasuda H, et al. Charles Bonnet syndrome: successful treatment of visual hallucinations due to vision loss with Yi-gan san. Prog. Neuropsychopharmacol Biol Psychiatry 2009b;33:382-383.
22. Gold K, Rabins PV Isolated visual hallucinations and the Charles Bonnet syndrome: a review of the literature and presentation of six cases. Compr Psychiatry 1989;30:90-95.
23. Teunisse RJ, Cruysberg JR, Hoefnagels WH, et al. Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome. Lancet 1996;347:794-797.
24. Cummings KL, Moga M, Gray K. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
25. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Shizophr Bull 1987;13:261-276.
26. Bartko JJ, Carpenter WT. On the methods and theory of reliability. J Nerv Ment Dis 1976;163:307-317.
27. Plummer C, Kleinitz A, Vroomen P. Of Roman chariots and goats in overcoats: the syndrome of Charles Bonnet J Clin Neurosci 2007;14:709-714.
28. Burke W. The neural basis of Charles Bonnet hallucinations: a hypothesis. J Neurol Neurosurg Psychiatry 2002;73:535-541.
29. Shimada Y, Goto H, Itoh T. Evaluation of the protective effects of alkaloids isolated from the hooks and stems of uncaria sinesis on glutamate-induced neuronal death in cultured cerebellar granule cells from rats. J Pharm Pharmacol 1999;51: 715-722.
30. Liao FF, Jan YM, Huang SY Evaluation with receptor binding assay on the water extracts of ten CNS-active Chinese herbal drug. Proc Natl Sci Counc Repub China B 1955;19:151-158.
31. Ishibashi A, Egashira N, Mishima K, et al. Study on the central action of Yoku-kan-san. Yakugaku Zasshi 2006;126(Supp 2):82-84.
32. Ichikawa K, Satoh-Nakagawa T, Maruyama M. A randomized observer-blind, controlled trial of the traditional Chinese medicine Yi-gan san for improvement ofbehavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry 2005;66:248-252.
33. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it Int J Epidemiol 2005;34:215-220.
34. Guy W, Ronato RR, eds. Manualfor the ECDEUAssessment Battery. 2. Rev Ed. Chevy Chase, MD: National Institute ofMental Health; 1970:12-1-12-6.